Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary
Company To Adopt ‘Dual Product Approach’ With Authorized Version
Months after obtaining the first US FDA designation of interchangeability, for its Semglee biosimilar to Sanofi’s Lantus, Viatris has seen a return on its investment, with the biosimilar scooping preferred status on one of the largest national formularies in the US.
